Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Legg-Calve-Perthes Disease and Thrombophilia

Legg-Calve-Perthes Disease and Thrombophilia Background: Thrombophilia has previously been identified as a potential etiologic factor in Legg-Calvé-Perthes disease. We prospectively studied the association between Legg-Calvé-Perthes disease and coagulation abnormalities by comparing seventy-two children who had the disease with 197 healthy controls. Methods: A nonselected, consecutive series of seventy-two patients with Legg-Calvé-Perthes disease (mean age and standard deviation, 6.6 ± 2.6 years) was studied in their order of referral and compared with 197 healthy controls (mean age, 7.6 ± 5.1 years). Assays were done for factor-V Leiden, prothrombin G20210A, methylenetetrahydrofolate reductase C677T, and plasminogen activator inhibitor-1 4G/5G gene mutations. Levels of anticardiolipin antibodies immunoglobulin G and M (IgG and IgM), homocysteine, protein C, protein S, antithrombin III, and plasminogen activator inhibitor-1 were also measured. Results: The factor-V Leiden mutation was more common in the patients (eight of seventy-two) than in the controls (seven of 197) (chi-square = 5.7, p = 0.017). After we controlled for the false-discovery rate, the case-control difference remained significant (p = 0.017). The odds ratio for the development of Legg-Calvé-Perthes disease in the presence of the factor-V Leiden mutation was 3.39 with a 95% confidence interval of 1.18 to 9.73. A high level of anticardiolipin antibodies (IgG and/or IgM) was found in nineteen of the seventy-two patients compared with twenty-two of the 197 controls (chi-square = 9.5, p = 0.002). After we controlled for the false-discovery rate, the case-control difference remained significant (p = 0.002). The odds ratio of patients with Legg-Calvé-Perthes disease having one or more abnormalities in factor V, anticardiolipin antibody IgG, or anticardiolipin antibody IgM as opposed to normal values for all three variables was 3.29 (95% confidence interval, 1.73 to 6.24; p = 0.0003). Conclusions: Two thrombophilic risk factors, the factor-V Leiden mutation and anticardiolipin antibodies, are associated with Legg-Calvé-Perthes disease, an association that may reflect causality. Level of Evidence: Prognostic study, Level II-1 (retrospective study). See Instructions to Authors for a complete description of levels of evidence. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Bone and Joint Surgery Wolters Kluwer Health

Loading next page...
 
/lp/jb-js/legg-calve-perthes-disease-and-thrombophilia-D0znmVsgyC

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2004 by The Journal of Bone and Joint Surgery, Inc.
ISSN
0021-9355
Publisher site
See Article on Publisher Site

Abstract

Background: Thrombophilia has previously been identified as a potential etiologic factor in Legg-Calvé-Perthes disease. We prospectively studied the association between Legg-Calvé-Perthes disease and coagulation abnormalities by comparing seventy-two children who had the disease with 197 healthy controls. Methods: A nonselected, consecutive series of seventy-two patients with Legg-Calvé-Perthes disease (mean age and standard deviation, 6.6 ± 2.6 years) was studied in their order of referral and compared with 197 healthy controls (mean age, 7.6 ± 5.1 years). Assays were done for factor-V Leiden, prothrombin G20210A, methylenetetrahydrofolate reductase C677T, and plasminogen activator inhibitor-1 4G/5G gene mutations. Levels of anticardiolipin antibodies immunoglobulin G and M (IgG and IgM), homocysteine, protein C, protein S, antithrombin III, and plasminogen activator inhibitor-1 were also measured. Results: The factor-V Leiden mutation was more common in the patients (eight of seventy-two) than in the controls (seven of 197) (chi-square = 5.7, p = 0.017). After we controlled for the false-discovery rate, the case-control difference remained significant (p = 0.017). The odds ratio for the development of Legg-Calvé-Perthes disease in the presence of the factor-V Leiden mutation was 3.39 with a 95% confidence interval of 1.18 to 9.73. A high level of anticardiolipin antibodies (IgG and/or IgM) was found in nineteen of the seventy-two patients compared with twenty-two of the 197 controls (chi-square = 9.5, p = 0.002). After we controlled for the false-discovery rate, the case-control difference remained significant (p = 0.002). The odds ratio of patients with Legg-Calvé-Perthes disease having one or more abnormalities in factor V, anticardiolipin antibody IgG, or anticardiolipin antibody IgM as opposed to normal values for all three variables was 3.29 (95% confidence interval, 1.73 to 6.24; p = 0.0003). Conclusions: Two thrombophilic risk factors, the factor-V Leiden mutation and anticardiolipin antibodies, are associated with Legg-Calvé-Perthes disease, an association that may reflect causality. Level of Evidence: Prognostic study, Level II-1 (retrospective study). See Instructions to Authors for a complete description of levels of evidence.

Journal

Journal of Bone and Joint SurgeryWolters Kluwer Health

Published: Dec 1, 2004

There are no references for this article.